Has Brexit placed the UK's healthcare sector under threat?

The UK healthcare sector is a major beneficiary of EU R&D funding, free-movement of scientists, and a regulatory framework that expedites product approvals across the continent, writes Quilter Cheviot's Amish Patel.

Replacing this funding, ensuring the UK remains an attractive destination for top scientific talent, and securing a central role for the UK regulatory body in the European Medical Agency will now be seen as priorities post-Brexit.  The outlook for quoted company earnings is different. The majority of UK healthcare stocks generate most of their revenue from outside the UK and thus would see a foreign exchange benefit from Brexit. Foreign corporates may also see a more attractive valuation gap that may lead to increased interest in UK stocks from an M&A perspective.  Brexit does not ...